|
-- advertisement --
|
Cardiovascular Risk
- CELEBREX may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. All NSAIDs may have a similar risk. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk (see WARNINGS and CLINICAL STUDIES).
- CELEBREX is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery (see WARNINGS).
Gastrointestinal Risk
- NSAIDs, including CELEBREX, cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events (see WARNINGS).
| | |
CELEBREX SUMMARY
CELEBREX is a nonsteroidal anti-inflammatory drug.
CELEBREX is indicated:
-
For relief of the signs and symptoms of osteoarthritis.
-
For relief of the signs and symptoms of rheumatoid arthritis in adults.
-
For the management of acute pain in adults (see CLINICAL STUDIES).
-
For the treatment of primary dysmenorrhea.
-
To reduce the number of adenomatous colorectal polyps in familial adenomatous polyposis (FAP), as an adjunct to usual care (e.g., endoscopic surveillance, surgery). It is not known whether there is a clinical benefit from a reduction in the number of colorectal polyps in FAP patients. It is also not known whether the effects of CELEBREX treatment will persist after CELEBREX is discontinued. The efficacy and safety of CELEBREX treatment in patients with FAP beyond six months have not been studied (see CLINICAL STUDIES, WARNINGS and PRECAUTIONS sections).
|
CELEBREX NEWS HIGHLIGHTS
Media Articles Related to Celebrex (Celecoxib)
Celebrex May Reduce Levels of Lung Cancer Biomarker
Source: MedicineNet celecoxib Specialty [2008.06.02]
Celebrex Plus Lipitor Could Fight Prostate Cancer
Source: MedicineNet atorvastatin Specialty [2008.04.15]
Published Studies Related to Celebrex (Celecoxib)
Celecoxib-related gastroduodenal ulcer and cardiovascular events in a randomized trial for gastric cancer prevention. [2008.07.28]
Perioperative celecoxib administration for pain management after total knee arthroplasty - a randomized, controlled study. [2008.06.03]
Cognitive Function Over Time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): Results of a Randomized, Controlled Trial of Naproxen and Celecoxib. [2008.05.12]
Celecoxib is a CYP1A2 inhibitor in vitro but not in vivo. [2008.05]
Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. [2008.05]
Clinical Trials Related to Celebrex (Celecoxib)
Study of Celebrex (Celecoxib) in Patients With Recurrent Respiratory Papillomatosis [Recruiting]
Celecoxib as Adjuvant Biologic Therapy in Patients With Head and Neck and Lung Cancer [Active, not recruiting]
Celebrex Total Knee Arthroplasty Study [Terminated]
Celecoxib (Celebrex) Versus Placebo in Men With Recurrent Prostate Cancer [Completed]
Study Of "Continuous Use" Of Celecoxib Vs. "Usual or Intermittent Use" [Completed]
|
|
Page last updated: 2008-08-10
|
|
-- advertisement --
|
